Movement Alert｜CARsgen Therapeutics-B Rises 5.19% in Regular Trading, Buyback Plan and Sector Rally Continue to Support Rebound

Market Focus07-02

On July 2, CARsgen Therapeutics-B rose 5.19% in regular trading, trading at HK$15.01/share, with turnover of HK$69.48 million. The stock continued its recovery trajectory following a sharp post-approval selloff.

The ongoing share buyback plan remains a key support factor. The board approved on June 25 a repurchase program authorizing the company to buy back up to approximately 30.12 million shares on the open market, representing about 5% of total issued shares as of May 31. The buyback is funded from non-IPO proceeds including business development income and interest income, signaling management confidence in the company's intrinsic value.

Sector-wide strength in biotech stocks further bolstered the rebound, with Akeso up 7.72%, SKB Bio up 7.66%, 3SBio up 7.46%, Innovent Bio up 6.85%, and BeiGene up 2.52%. The stock had previously declined over 20% cumulatively in four trading sessions following the landmark approval of its solid tumor CAR-T product Satri-Cel on June 22, amid market concerns over near-term commercialization scale at approximately RMB 990,000 per injection.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1191082168?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 15:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1191082168","market":"us","top_or_hot":-1,"title":"Movement Alert｜CARsgen Therapeutics-B Rises 5.19% in Regular Trading, Buyback Plan and Sector Rally Continue to Support Rebound","media":"Market Focus","content":"<p><p>On July 2, CARsgen Therapeutics-B rose 5.19% in regular trading, trading at HK$15.01/share, with turnover of HK$69.48 million. The stock continued its recovery trajectory following a sharp post-approval selloff.</p><p>The ongoing share buyback plan remains a key support factor. The board approved on June 25 a repurchase program authorizing the company to buy back up to approximately 30.12 million shares on the open market, representing about 5% of total issued shares as of May 31. The buyback is funded from non-IPO proceeds including business development income and interest income, signaling management confidence in the company's intrinsic value.</p><p>Sector-wide strength in biotech stocks further bolstered the rebound, with Akeso up 7.72%, SKB Bio up 7.66%, 3SBio up 7.46%, Innovent Bio up 6.85%, and BeiGene up 2.52%. The stock had previously declined over 20% cumulatively in four trading sessions following the landmark approval of its solid tumor CAR-T product Satri-Cel on June 22, amid market concerns over near-term commercialization scale at approximately RMB 990,000 per injection.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜CARsgen Therapeutics-B Rises 5.19% in Regular Trading, Buyback Plan and Sector Rally Continue to Support Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜CARsgen Therapeutics-B Rises 5.19% in Regular Trading, Buyback Plan and Sector Rally Continue to Support Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 15:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, CARsgen Therapeutics-B rose 5.19% in regular trading, trading at HK$15.01/share, with turnover of HK$69.48 million. The stock continued its recovery trajectory following a sharp post-approval selloff.</p><p>The ongoing share buyback plan remains a key support factor. The board approved on June 25 a repurchase program authorizing the company to buy back up to approximately 30.12 million shares on the open market, representing about 5% of total issued shares as of May 31. The buyback is funded from non-IPO proceeds including business development income and interest income, signaling management confidence in the company's intrinsic value.</p><p>Sector-wide strength in biotech stocks further bolstered the rebound, with Akeso up 7.72%, SKB Bio up 7.66%, 3SBio up 7.46%, Innovent Bio up 6.85%, and BeiGene up 2.52%. The stock had previously declined over 20% cumulatively in four trading sessions following the landmark approval of its solid tumor CAR-T product Satri-Cel on June 22, amid market concerns over near-term commercialization scale at approximately RMB 990,000 per injection.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02171","symbol_name":"科济药业-B","start_time":0,"source_url":"","article_id":"1191082168","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1191082168","pubTimestamp":1782976332,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, CARsgen Therapeutics-B rose 5.19% in regular trading, trading at HK$15.01/share, with turnover of HK$69.48 million. The stock continued its recovery trajectory following a sharp...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02171":"科济药业-B"},"translate_title":"走势提示|科济生物-B常规交易涨5.19%回购计划及板块涨势继续支撑反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1},"content_text":"On July 2, CARsgen Therapeutics-B rose 5.19% in regular trading, trading at HK$15.01/share, with turnover of HK$69.48 million. The stock continued its recovery trajectory following a sharp post-approval selloff.The ongoing share buyback plan remains a key support factor. The board approved on June 25 a repurchase program authorizing the company to buy back up to approximately 30.12 million shares on the open market, representing about 5% of total issued shares as of May 31. The buyback is funded from non-IPO proceeds including business development income and interest income, signaling management confidence in the company's intrinsic value.Sector-wide strength in biotech stocks further bolstered the rebound, with Akeso up 7.72%, SKB Bio up 7.66%, 3SBio up 7.46%, Innovent Bio up 6.85%, and BeiGene up 2.52%. The stock had previously declined over 20% cumulatively in four trading sessions following the landmark approval of its solid tumor CAR-T product Satri-Cel on June 22, amid market concerns over near-term commercialization scale at approximately RMB 990,000 per injection.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1191082168","isCrawlerRequest":true}